首页 | 本学科首页   官方微博 | 高级检索  
     

反应停治疗难治性多发性骨髓瘤6例
引用本文:陈文新,李新,刘雪梅,包翠华. 反应停治疗难治性多发性骨髓瘤6例[J]. 内蒙古医学杂志, 2003, 35(6): 497-499
作者姓名:陈文新  李新  刘雪梅  包翠华
作者单位:1. 内蒙古医学院第三附属医院血液科,内蒙古,包头,014010
2. 呼和浩特市新城区医院,内蒙古,呼和浩特,010010
摘    要:目的:探讨反应停治疗难治性多发性骨髓瘤(MM)的临床疗效。方法:对6例难治疗性多发性骨髓瘤应用反应停治疗后的临床资料进行分析,并结合文献复习,为该病的治疗提供一条思路。结果:1例患者达完全缓解;1例患者达部分缓解;1例进步,血清M蛋白减少35%、骨痛明显减轻、血沉降低40%、血红蛋白上升20g/L;2例无效;1例死亡。结论:反应停对多发性骨髓瘤有较好的疗效,不良反应可以耐受且不产生骨髓抑制:抗血管新生是其主要疗效机制。

关 键 词:难治性多发性骨髓瘤 反应停 药物治疗 抗血管新生 疗效
文章编号:1004-0951(2003)06-0497-03
修稿时间:2003-04-25

Thalidomide in Therapy of Refractory Multiple Myeloma: Report of 6 Cases
CHEN Wen-xin,LI Xin,LIU Xue-mei,BAO Chui-hua. Thalidomide in Therapy of Refractory Multiple Myeloma: Report of 6 Cases[J]. Inner Mongolia Medical Journal, 2003, 35(6): 497-499
Authors:CHEN Wen-xin  LI Xin  LIU Xue-mei  BAO Chui-hua
Abstract:Objective:To inquire the treatment outcome of thalidomide for refractory multiple myiloma.Method:The clinical data of t myeloma treated with thalicomide were reviewed.Result:The were 1 case remitted,1 case remitted partly,1 case effective with decreased serum M protein(35%),relieved ostalgia,lower erythrocyte sedimentation rate (CSR)(40%) and increased hemoglobin(20g/L),2 cases ineffective and 1 case dead.Conclusion:Thalidomide is effective for multiple myeloma with tolerable side-effect and noninhibiton of bone marrow.Antivascularization is its main mechanism.
Keywords:Multiple myeloma  Thalidomide  Therapy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号